ScholarMate
English简体中文繁體中文
客服热线:400-1616-289
登录注册
期刊论文

Identifying Mild Cognitive Impairment with Random Forest by Integrating Multiple MRI Morphological Metrics

Ma, Zhe; Jing, Bin; Li, Yuxia; Yan, Huagang; Li, Zhaoxia; Ma, Xiangyu; Zhuo, Zhizheng; Wei, Lijiang; Li, Haiyun*capital med univ
JOURNAL OF ALZHEIMERS DISEASE2020DOI: 10.3233/JAD-190715
17被引4阅读
引用收藏
分享

摘要

Mild cognitive impairment (MCI) exhibits a high risk of progression to Alzheimer's disease (AD), and it is commonly deemed as the precursor of AD. It is important to find effective and robust ways for the early diagnosis of MCI. In this paper, a random forest-based method combining multiple morphological metrics was proposed to identify MCI from normal controls (NC). Voxel-based morphometry, deformation-based morphometry, and surface-based morphometry were utilized to extract morphological metrics such as gray matter volume, Jacobian determinant value, cortical thickness, gyrification index, sulcus depth, and fractal dimension. An initial discovery dataset (56 MCI/55 NC) from the ADNI were used to construct classification models and the performances were testified with 10-fold cross validation. To test the generalization of the proposed method, two extra validation datasets including longitudinal ADNI data (30 MCI/16 NC) and collected data from Xuanwu Hospital (27 MCI/32 NC) were employed respectively to evaluate the performance. No matter whether testing was done on the discovery dataset or the extra validation datasets, the accuracies were about 80% with the combined morphological metrics, which were significantly superior to single metric (accuracy: 45%similar to 76%) and also displayed good generalization across datasets. Additionally, gyrification index and cortical thickness derived from surface-based morphometry outperformed other features in MCI identification, suggesting they were some key morphological biomarkers for early MCI diagnosis. Combining the multiple morphological metrics together resulted in a significantly better and reliable identification model, which may be helpful to assist in the clinical diagnosis of MCI.

学科与关键词

关键词
Deformation-based morphometrymild cognitive impairmentrandom forestsurface-based morphometryvoxel-based morphometry
相关
加载中…
  • Diagnostic Classification and Biomarker Identification of Alzheimer's Disease with Random Forest Algorithm
    Song, Minseok; Jung, Hyeyoom; Lee, Seungyong; Kim, Donghyeon; Ahn, Minkyu*Brain Sciences, 2021, 11(4): 453.被引 35
  • Voxel-based morphometry and a deep learning model for the diagnosis of early Alzheimer's disease based on cerebral gray matter changes
    Huang, Huaidong; Zheng, Shiqiang; Yang, Zhongxian; Wu, Yi; Li, Yan; Qiu, Jinming; Cheng, Yan; Lin, Panpan; Lin, Yan; Guan, Jitian; Mikulis, David John; Zhou, Teng*; Wu, Renhua*Cerebral Cortex, 2023, 33(3): 754-763.被引 16
  • Multi-Atlas Based Representations for Alzheimer's Disease Diagnosis
    Min, Rui; Wu, Guorong; Cheng, Jian; Wang, Qian; Shen, Dinggang*HUMAN BRAIN MAPPING, 2014, 35(10): 5052-5070.被引 58
查看全部 →

发表信息

论文状态
公开发表
期刊
JOURNAL OF ALZHEIMERS DISEASE
发表日期
2020
卷期
第 73 卷, 第 3 期
页码
991-1002
DOI
10.3233/JAD-190715
语言
ENGLISH
期刊收录
NSL.SCIE
期刊等级
3区
成果收录
SCIE
资助标注
Beijing Natural Science Foundation [7174282, 7182019, 4122018]; Scientific Research Common Program of Beijing Municipal Commission of Education; China Postdoctoral Science Foundation [2018M641414]; Beijing Postdoctoral Research Foundation [ZZ201912]; Alzheimer's Disease Neuroimaging Initiative (ADNI) (National Institutes of Health) [U01AG024904]; DODADNI (Department of Defense) [W81XWH-12-2-0012]; National Institute on Aging; National Institute of Biomedical Imaging and Bioengineering; AbbVie; Alzheimer's Association; Alzheimer's Drug Discovery Foundation; Araclon Biotech; BioClinica, Inc.; Biogen; BristolMyers Squibb Company; CereSpir, Inc.; Cogstate; Eisai Inc.; Elan Pharmaceuticals, Inc.; Eli Lilly and Company; EuroImmun; F. Hoffmann-La Roche Ltd and its affiliated company Genentech, Inc.; Fujirebio; GE Healthcare; IXICO Ltd.; Janssen Alzheimer Immunotherapy Research & Development, LLC.; Johnson & Johnson Pharmaceutical Research & Development LLC.; Lumosity; Lundbeck; Merck Co., Inc.; MesoScale Diagnostics, LLC.; NeuroRx Research; Neurotrack Technologies; Novartis Pharmaceuticals Corporation; Pfizer Inc.; Piramal Imaging; Servier; Takeda Pharmaceutical Company; Transition Therapeutics; Canadian Institutes of Health Research

作者

  • M

    Ma, Zhe (第一作者)

    capital med univ

  • J

    Jing, Bin

    capital med univ

查看全部 9 位作者收起作者
  • L

    Li, Yuxia

    capital med univ

  • Y

    Yan, Huagang

    capital med univ

  • L

    Li, Zhaoxia

    capital med univ

  • M

    Ma, Xiangyu

    capital med univ

  • Z

    Zhuo, Zhizheng

    capital med univ

  • W

    Wei, Lijiang

    capital med univ

  • L

    Li, Haiyun (通讯)

    capital med univ

登录解锁更多功能

  • 收藏这篇,随时在“我的 · 收藏”找回
  • 认领你的成果,生成推广素材
  • 关注作者获取最新成果
  • 加入项目组、协同写作
注册 / 登录

产品服务

  • 科研之友
  • 创新城
  • 科创云

服务支持

  • 帮助中心
  • 隐私政策
  • 服务条款

联系方式

在线客服:【】
客服热线:400-1616-289
电子邮箱:support@scholarmate.com

关注或下载科研之友

微信二维码
微信公众号
客户端下载二维码
下载客户端
科研成果科研人员科研机构科研动态爱瑞思软件

©2026 深圳市科研之友网络服务有限公司

公安备案图标粤公网安备 44030502000213
粤ICP备 16046710 号粤B2-20110417